Ohcanbohtosat - Birgit Bossenmaier
- Čájehuvvo 1 - 14 / 14
-
1
Acquired Resistance to Antibody-Drug Conjugates Dahkki Denis M. Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner
Almmustuhtton 2019Revisão -
2
-
3
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models Dahkki Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann
Almmustuhtton 2009Artigo -
4
Differential activities of protein tyrosine phosphatases in intact cells. Dahkki Reiner Lammers, Birgit Bossenmaier, D E Cool, N. K. Tonks, Joseph Schlessinger, E H Fischer, A. Ullrich
Almmustuhtton 1993Artigo -
5
Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. Dahkki G Kroder, Birgit Bossenmaier, Monika Kellerer, Edison Capp, B Stoyanov, A Mühlhöfer, Lucia Berti, Hiroyoshi Horikoshi, A. Ullrich, Hans-Ulrich Häring
Almmustuhtton 1996Artigo -
6
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer Dahkki Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier
Almmustuhtton 2017Artigo -
7
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity Dahkki Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K. Bera, Masaki Terabe, Jay A. Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin‐Hsien Tai, Yoram Reiter, Ira Pastan
Almmustuhtton 2017Artigo -
8
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation Dahkki Christian Mirschberger, Christian Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A. Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl‐Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier
Almmustuhtton 2013Artigo -
9
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab Dahkki Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña
Almmustuhtton 2012Artigo -
10
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116 Dahkki Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj, Carolien P. Schröder, Linda Pot, Birgit Bossenmaier, Marlène Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G.W. Kosterink, Elisabeth G.E. de Vries
Almmustuhtton 2014Artigo -
11
Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy Dahkki Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff, Roland F. Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan Olaf Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner
Almmustuhtton 2016Artigo -
12
The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner Dahkki Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer‐Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Rivière, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Véronique Blanc, Shane A. Olwill
Almmustuhtton 2022Artigo -
13
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors Dahkki Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, Álvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas, Andrés Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau‐Sørensen, Marlène Thomas, Maurizio Ceppi, Georgina Meneses‐Lorente, Ian James, Céline Adessi, Francesca Michielin, K. Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Maja Weisser, Ulrik Lassen
Almmustuhtton 2015Artigo -
14
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer Dahkki Denis M. Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy Gately, Clare Hughes, Anthony M. Davies, Thamir Mahgoub, Jo Ballot, Sinéad Toomey, Darran P. O’Connor, William M. Gallagher, Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Bryan T. Hennessy, Kenneth J. O’Byrne, Max Hasmann, Birgit Bossenmaier, Norma O’Donovan, John Crown
Almmustuhtton 2020Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Biology
Cancer research
Antibody
Biochemistry
Immunology
Medicine
Monoclonal antibody
Internal medicine
Cancer
In vitro
Receptor
Chemistry
Pharmacology
Biotechnology
Cell biology
Endocrinology
In vivo
Antigen
Breast cancer
Cytotoxicity
Gene
Immune system
Phosphorylation
Tyrosine kinase
Tyrosine phosphorylation
Autophosphorylation
CD8
Cytotoxic T cell
Humanized antibody
Immunotoxin